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Summary
Advanced glycosylation endproducts (AGEs), the glucose-derived adducts that form nonenzy-
matically and accumulate on tissue proteins, are implicated inmany chronic complications associated
with diabetes and aging . We have previously described a monocyte/macrophage surface receptor
system thought to coordinate AGE protein removal and tissue remodeling, and purified a cor-
responding 90-kD AGE-binding protein from the murineRAW 264.7 cell line. To identify AGE-
binding proteins in normal animals, the tissue distribution of 125I-AGE rat serum albumin taken
up from the blood was determined in rats in vivo. These uptake studies demonstrated that the
liver was a major site ofAGE protein sequestration . Using a solid-phase assay system involving
the immobilization of solubilized membrane proteins onto nitrocellulose to monitor binding
activity, and several purification steps including affinity chromatography over an AGE bovine
serum albumin matrix, two rat liver membrane proteins were isolated that specifically bound
AGES, one migrating at 60 kD (p60) and the other at 90kD (p90) on SDS-PAGE . NH2-terminal
sequence analysis revealed no significant homology between these two proteins nor to any molecules
available in sequence databases. Flow cytometric analyses using avian antibodies to purified rat
p60 and p90 demonstrated that both proteins are present on rat monocytes and macrophages.
Competition studies revealed no crossreactivity between the two antisera; anti-p60 and anti-p90
antisera prevented AGE-protein binding to rat macrophages when added alone or in combination .
These results indicate that rat liver contains at least two novel and distinct proteins that recognize
AGE-modified macromolecules, although p90 may be related to the previously described 90-kD
AGE receptor isolated fromRAW 264.7 cells . The constitutive expression ofAGE-binding proteins
on rat monocytes and macrophages, and the sequestration ofcirculating AGE-modified proteins
by the liver, provides further evidence in support of a role for these molecules in the normal
removal of proteins marked as senescent by accumulated glucose-derived covalent addition products,
or AGES .
G
lucose and other reducing sugars attach nonenzymatical
ly to the amino groups of proteins in a concentration-
dependent manner. Over time, these initial Amadori adducts
undergo further rearrangements, dehydrations, and cross-
linking with other proteins to accumulate as a family ofcom-
plex structures that are referred to as advanced glycosylation
endproducts (AGEs)t . Although this chemistry has been
studied by food chemists for many years, it was only in the
past decade that the presence of AGES in living tissues has
t Abbreviations used in thispaper. AGE, advanced glycosylation endproduct ;
FFI, 2-furoyl-4(5)-(2-fumnyl)-1H-imidazole; NC, nitrocellulose ; RSA, rat
serum albumin; TBIR, tissue-to-blood isotope ratio.
515
been established . The excessive deposition of these products
on structural body proteins as a function of age and elevated
glucose concentration, (1) taken together with evidence of
effective prevention of tissue pathology by an AGE inhibitor,
aminoguanidine (2), has lent support to the hypothesis that
the formation ofAGES plays a role in the long term compli-
cations of aging and diabetes .
Since the amount ofAGES found in human tissues is less
than could be predicted from protein/glucose incubation
studies in vitro, we proposed several years ago that there might
be normal mechanisms to remove those long-lived proteins
that had accumulated AGES in vivo. In fact, monocytes/mac-
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activity specific for AGE moieties, independent of the pro-
tein that wasAGEmodified . This macrophage AGEreceptor
was shown to differ from other known scavenger receptors
on these cells (3, 4) . The uptake and degradation of senes-
cent, AGE-modified proteins by macrophageswasalso shown
to be associated with the release of potent, multifunctional
cytokines (IIA andTNF [5]) and growth factors (PDGF [6]
and IGF-1[7]), suggesting that theAGEreceptor system plays
an important role in normal tissue remodeling. Recently, we
have isolated a 90-kD protein from the membranes of the
mouse macrophage cell line, RAW 264.7, which binds
specifically to AGE proteins as well as to a chemically pre-
pared modelAGE compound, 2-(2-furoyl)-4(5)-(2-furanyl)-
1H-imidazole, or FFI (8, 9) .
Several other cell types, e.g., human endothelial (10) and
mesangial cells (11), as well as human fibroblasts (12) also
express membrane proteins that bind AGE-modified proteins ;
however, none of these recognize the modelAGE compound,
FFI . The exposure of endothelial cells in vitro to AGE pro-
teins promotes procoagulant activity, associated with decreased
membrane-associated thrombomodulin and increasedproduc-
tion of tissue factor, as well as disruption of the barrier in-
tegrity of cultured endothelial monolayers (10) . Theinterac-
tion ofmesangial cells or fibroblasts withAGEprotein appears
to stimulate . increased matrix protein synthesis (11) and al-
teredmitogenic activity (11, 12). Given the differentbinding
specificitiesand functional characteristics ofthe AGE receptors
present on these cell types compared to the receptor identified
on macrophages, it is not clear whether these molecules are
interrelated .
In the present paper, we report the purification from rat
liver, and partial amino acid sequences, of two membrane
proteins of -60 and -90 kD, respectively, that bind AGE-
modified proteins. Both of these proteins are expressed on
the surface of rat monocytes and resident peritoneal macro-
phages, suggesting arelationship to theAGEreceptor system
earlier identified on these cells and believed to be involved
in tissue repair and remodelling.
Materials and Methods
Chemicals and Reagents.
￿
BSA (fraction V), bovine ribonuclease,
glucosamide-BSA, glucose-6-phosphate, and collagen Iwere pur-
chased from Sigma Chemical Co. -(St . Louis, MO). Triton X-114
and Triton X-100were purchased from Boehringer Mannheim Bio-
chemicals (Indianapolis, IN) . Sodium 121iodide was obtained from
New England Nuclear (Boston, MA). Nitrocellulose membranes
were from Schleicher & Schuell (Keene, NH) . CNBr-activated
Sepharose 4B waspurchasedfrom Pierce ChemicalCo. (Rockford,
IL) . LDLandacetyl-LDL were the generous gift ofDr. DavidVia
(Baylor College of Medicine, Houston, TX). 2-(2-furoyl)-4(5)-(2-
furanyl)-1H-imidazole (FFI)' and its derivative, FFI-hexanoic acid
(FFI-HA) were kindly provided by Dr. Peter Ulrich (Geritech Inc.,
Northvale, NJ).
Preparation ofAGE Proteins and Formaldehyde-modified Proteins.
AGE-BSA, AGE rat serumalbumin (RSA), AGE ribonuclease, and
AGE collagen I were generated by standardized methods as previ-
ously described in detail (3) . In brief, each protein solution (25
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mg/ml) was incubated with either 0.5 M glucose or glucose-6-
phosphate in 100mM phosphate buffer (pH 7 .4) at 37°C for 6
wk under sterile conditions, and then lowmolecularweight reac-
tants were removedby dialysis against PBS (20mM sodium phos-
phate buffer containing 0.15M NaCl, pH 7.4) . FFI-HA was cou-
pled to BSA with the water-soluble carbodiimide, EDAC, as
described previously (13). Characteristic fluorescence of the AGE
proteins was observed at 450 nm upon excitation at 390nm (14) .
Formaldehyde-modifiedBSAwas prepared as described (15), by in-
cubatingBSA in0.1M sodium carbonate buffer (pH 10) with 0.33
M formaldehyde at 37°C for 5 h, followed by extensive dialysis
against PBS. All protein concentrations were determined by the
method of Bradford (16) . Protein and AGE protein preparations
were radio-labeled with 1211 by theIodo-Gen method (17) . 2mg of
AGE-BSA was incubated with 25 mCi carrier-free "'I in an Iodo-
gen-coated glass vial at room temperature for 45 min . To separate
free from bound 1251, the sample was fractionated by Sephadex
G-25M column chromatography and dialysis against PBS, until at
least 98% of the 1251 was TCA precipitabl . The specific radioac-
tivity of the labeled 1251-AGE-BSA was between 8,000 and 15,000
cpm/ng protein .
BSAand AGE-BSA Sepharose were prepared by reacting either
BSAor AGE-BSA (25 mg/ml) with CNBr-Sepharose gel (5 ml/g
ofdrypowder) according to the manufacturers instructions, in coup-
ling buffer (0.1MNaHC05, 0.5M NaCl, pH 8.3) . The mixture
was rotated for2h at room temperature. Excess ligand waswashed
from the resinwith coupling buffer andthen with Tris-HCI buffer
(0 .1 M, pH 8.0) for 2 h at room temperature to block remaining
active groups. The resinwas then washed with three cycles of so-
dium acetate buffer (0 .1 M, pH 4) containing NaCl (0.5 M), fol-
lowedby Tris-HCI buffer (0.1M,pH 8) containing NaCI (0.5 M),
and stored at 4-8°C.
In Vivo Studies.
￿
For tissue distribution studies, AGE-RSAwas
prepared as described above (4), and radioiodinated to a specific
activity of 8 .3 x 105 cpm/ug . Similarly, normal RSA was iodi-
nated to a specific activity of 6.2 x 101 cpm/tag. Freshly drawn
rat RBC were labeled with 5'Cr to allow subsequent correction
for tissue counts for blood-associated radioactivity. Approximately
1 mCi of "Cr was added to 10 ml RBC, mixed thoroughly, and
allowed to incubate for 30 min at room temperature before washing
with PBS containing 1% BSA and 0.1% dextrose until superna-
tant radioactivity was<1% of that in the packed RBC (18) . Buffer
was added to labeled RBCto obtain ahematocrit of40% and the
labeled RBC were used immediately.
To determine the tissue distribution ofAGE ligands, normal male
Sprague-Dawley rats (200 g) were divided into groups of five, and
anesthetized with sodium pentobarbital (40 mg/kg) . Allanimals
received an injection of"Cr-RBC (0.65 ml, i.v.) 5 min before the
labeled ligand . The indicated groups of rats received either 'asI-
AGE-RSA (50 Fig in 0.1 ml, i.v.) or an identical amount of 1151-
normal RSA . At the indicated time intervals, 0.5-m1 aliquots of
blood were drawn and various organs were removed andcounted
for radioactivity (19) . The specificity ofAGEligand uptake in var-
ious organs was assessed by injecting groups ofanimalswith excess
nonlabeled AGE-BSA (5 mg) 2 min before administration of 50
Fig of 1211-AGE-BSA . After 5, 20, and 60 min, 0.5-ml blood
samples were collected, animals were killed, and various organs
and tissueswere collectedandcounted for radioactivity. TheRBC
were lysedwith water, and protein was precipitatedwith20%TCA.
Theorgans were weighed, homogenized with ahand homogenizer,
protein was precipitated with20% TCA, andcounted for radioac-
tivity. The tissue-to-blood isotope ratio (TBIR) was calculated by
the formula : TBIR = ("'I/11Cr in tissue)/(1211/"Cr in blood)
Advanced Glycosylation Endproduct-binding Proteins in Rat Liver(20). TBIR is a dimensionless index of the degree to which any
tissue sample has sequestered labeled ligand relative to the blood .
Solubilization andFractionation ofHepaticMembmne Proteins. Liver
membranes were prepared according to the method of Thom et
al . (21), with some modifications.For a typical membrane prepara-
tion, 14 g of rat liver was homogenized in 80 ml THEbuffer (50
mM Tris-HCl buffer [pH8.0], containing 150mM NaCl, 0.1 mM
EDTA, and 23 wg/ml PMSF andcentrifuged for 10 min at 3,000
g. The supernatant was layered on top of a solution of40% su-
crose in THE buffer, andcentrifuged at 24,000g for 1 h at 4°C.
The membranes were collected from the interface with a Pasteur
pipette. Themembrane preparation was solubilized inTHEbuffer
containing 2% Triton X-114 at 4°Cand clarified by centrifugation
for 30 min at 100,000 g . The supernatant was then warmed to
30°C and the detergent phase, aqueous phase, and detergent-
insoluble pellet were separated according to the phase separation
method described by Bordier (22) . The resulting detergent phase
was either used directly for purification of AGE-binding proteins
or diluted .1:10withPBS containing2% Triton X-100and 2mM
PMSF. This material (D phase) wasfrozen at -80°Cuntil further
use.
In Vitro Solidphase AGE-binding Assay .
￿
AGE-binding activity
was determined by amodified version of solid-phase binding assay
developed for the l1rl receptor (23) . Aliquots ofdetergent-solubilized
membrane proteins were blotted onto grid-marked nitrocellulose
(NC) membranes . The blotswere dried at room temperature and
could be stored at room temperature for severalweekswithout ap-
parent loss ofbinding activity. TheNC membraneswere cut into
small squares (0.9 cm2) with the immobilized protein at the center
and distributed in 24-well trays (Costar, Cambridge, MA).Immobi-
lized protein was reconstituted in PBS, pH 7.4, containing 0.5%
Triton X-100 for30-60min at room temperature. The blots were
subsequently incubated in blocking buffer (PBS,pH 7.4, containing
2% BSA, 0.2% Triton X-100, and 1 MM MgCl 2) for 2 h with
agitation at 4°C . Specific ligandbindingwas carried out by adding
50-100 nM "IAGE-BSA directly to the blocking buffer and
agitating at 4°C for a further 1.5 h. TheNC membranes were
transferred to a new tray and rinsed quickly three times with PBS
containing 0.2% Triton X-100, followed by two additional 10-min
washings with PBS. Ligand bindingwas then evaluatedby autora-
diography or gamma counting.
LigandBlotting.
￿
SDS-PAGE and electro-blotting were performed
as previously described (24) . Proteins were electrophoretically sepa-
rated on either 8-16% or4-20% gradient polyacrylamide gels. After
electro-blotting the proteins from the gel onto NC membranes,
the blots were washed at 4°Covernight with PBScontaining0.2%
Triton X-100 . The blots were then incubated in blocking buffer
for 3 h at 4°C with agitation . Ligand binding was performedby
adding 10 nM "5I-AGE-BSA to the blocking buffer. After 1.5-2
h at 4°C, the blots were washed three timeswith blocking buffer
for 1 min each and two times for 10 min each . After air drying,
the ligand binding was evaluated by autoradiography.
Isolation ofp60andp90from RatLiver Membranes.
￿
Unless other-
wise indicated, all purification procedures were performed at 4°C .
The detergent phase of the rat membrane preparation (D phase,
-860 mg protein) was applied to a polyethylenimine cellulose
column (PEI) (3 x 30 cm) equilibrated with THE buffer. After
washing with equilibration buffer (TNE plus 2mM PMSF con-
taining 1% CHAPS), the proteins bound to thePEI column were
eluted by a240-ml linear gradient of0.1-1.5MNaCl in theequilibra-
tion buffer. Fractions were analyzed for binding activityby the solid-
phase AGE binding assay. The active fractions were pooled and
dialyzed overnight against TNE buffer containing 1% CHAPS.
ThePEIpool (160mg protein, 80 ml)wasthen applied to aDEAE-
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cellulose column (2.5 x 20 cm) previously equilibrated with
THE/CHAPS/PMSF equilibration buffer. Thecolumn was washed
with four-column volumes of equilibration buffer and proteins were
eluted by a 200-ml linear gradient of 0.2-1.5M NaCI in equilibra-
tion buffer. The fractions that containedAGE-BSA binding activity
were pooled and concentrated by ultrafiltration (Centricon 10 ;
Amicon) . The concentrated DEAE pool (80 mg protein) was cy-
cled three timesthroughaBSA-Sepharose4B column (2 x 12 cm,
10 mg of BSA per ml of gel), to eliminate proteins that bound
to BSA. The flow-through from this BSA-Sepharose column was
then applied to an AGE-BSASepharose 4B column (2 x 6 cm,
10 mg ofAGE-BSA perml of gel) and cycled twice. Thecolumn
was washed with 25-columnvolumes ofPBS buffer, pH 7.4, con-
taining 0.2% Triton X-100, and 1mM PMSF. The proteinsbound
to theAGE-BSA column were eluted with the step-wise addition
of PBS buffer containing 1.5 M NaCl, 0.2% Triton X-100, and
1mM PMSF . Each fraction was dialyzed against PBS containing
1mM PMSF, concentrated by ultrafiltration (Centricon 30,Amicon)
and analyzed for '15I-AGE-BSA binding activity by the solid-phase
binding assay.
Preparative electrophoresis was performed as described in detail
elsewhere (25) . In brief, 50 FAg of the protein mixture that had
been affinity purified overAGE-BSAwas boiled for3 min in sample
buffer (0.03M Tris-HCI, pH 6.8, 1% SDS, 5% glycerol, 0.015%
Bromophenol Blue) in the presence of 0.1 M 2-mercaptoethanol
and subjected to electrophoresis through 10%polyacrylamide gels
in the presence of0.1% SDS . The60-kD and 90-kD protein bands
were excised and electro-eluted (Elutrap ; Schleicher& Schuell) in
Tris buffer (25 mM,pH 8.5) containing glycine (192mM) and0.1%
SDS, as described (26) .
Antibody Generation.
￿
Laying hens were injected subcutaneously
at multiple sites with a total of 100-150 fAgof electrophoretically
purified p60or p90 in CFA(Pocono Rabbit Farm and Laboratory,
Canadensis, PA) . On days 14 and 21, the hens were injected with
an additional 60 pg ofeach protein inCFA . Further boosts of80-100
jug of the corresponding proteins in IFA were given 1 mo after
the initial series . Eggs and serum from the chickens immunized
with p60 or p90 proteins were separately collected . Igs from the
yolkswere extracted according to themethod of Polson et al . (27),
whileserumIgswere isolated by acombination ofammonium sul-
phate (30%) precipitation andDEAEcellulosechromatography (28).
Western Blotting .
￿
10-,ug aliquots ofdetergent-solubilized samples
ofmembrane protein were boiled in sample buffer in the presence
of 0.1 M 2-mercaptoethanol, and subjected to electrophoresis
through gradient gels (8-16%). After transferring onto nitrocel-
lulose, the membranes were rinsed in TBS-t buffer (10mM Tris,
150mM NaCl, 0.05% Tween20) and blockedwith TBS-t buffer
containing 2% BSA for 1 h at 4°C. The blots were probed with
either anti-60kD or anti-90kD avianIgG or pre-immune chicken
IgG (10 wg/ml) for 60 min at 4°C and then washed with TBS-t
buffer three times, for 5mineach . The blots were then incubated
with goat anti-chicken alkaline phosphatase conjugate (1:1,000 di-
lution) for 1 h at 4°C. Colordevelopment was achieved according
to instructions of the manufacturer (Promega, Cleveland, OH).
Flow Cytometric Analysis: Cell Preparation .
￿
Heparinized blood
wasdrawnfrom male Sprague-Dawley rats (200-300 g) by cardiac
puncture. Purified monocytes were prepared over Ficoll-Hypaque
(29) and Percoll gradients (30). Resident rat peritoneal macrophages
were obtained from rats by washing the peritoneal cavity with 20
ml of PBS (4) and were characterized by flow cytometry.
Flow Cytometric Analysis: Fluorescence Flow Cytometry .
￿
The ex-
pression of p60and p90 AGE-binding proteins on rat monocytes
andmacrophages wasdetermined by indirect immunofluorescence.
Single-color cell staining was performed by incubating 10 6 cellswith biotinylated anti-p60 or anti-p90 primary antibodies at a final
concentration of 5 lAg/ml for 20 min at 4°C. Cells were washed
in staining buffer (PBS, 3% FBS, 0.1% NaN3) and then incubated
with FITC-conjugated avidin (Becton Dickinson & Co., Moun-
tain View, CA) . Background fluorescence was determined by
staining the cells with a relevant isotypic control antibody, bi-
otinylated chicken IgG used in identical concentrations (5 Ag/ml) .
Cells were analyzed using aFACSCAN® (Becton Dickinson&Co.)
with gates setby forward anglelight scatter and side scatter. Fluores-
cence emission for FITC was detected by selectively collecting at
500-537nm on at least 5,000 labeled cells, gated to include mono-
cytes/macrophages and to exclude lymphocytes, other nonmono-
cytic cells and dead cells. The data were analyzed by Paint-A-Gate
software (Consort 30 ; Becton Dickinson & Co .) .
For the cross-competition study, 106 rat monocytes were treated
with either 5 ug/ml biotinylated anti-p60 antibodies in the pres-
ence of20-fold excess anti-p90 antibodies, or 5 pg/20 ltl biotinylated
anti-p90 in the presence of 20-fold excess anti-p60 . The antibody-
treated cells were then labeled using FITC-avidin and analyzed by
flow cytometry .
Results
In Vivo Tissue Distribution ofAGE-binding Activity .
￿
We have
previously identified a 90-kD protein on mouse and human
monocytes/macrophages which selectively binds AGE pro-
teins (3, 4, 8, 9) . Since these sources are not convenient to
provide sufficient material for further biochemical character-
ization, we searched for alternate tissue sources. As a first
step, the distribution of AGE-specific binding activity in rat
tissues was examined by uptake studies of 1251-AGE-RSA . Ei-
ther 1251-AGE-RSA (50 hg, 8.3 x 105 cpm/p.g) or 125I_
normal RSA (50 Nq, 6.2 x 10 5 cpm/,Lg) was injected
intravenously into rats along with "Cr-labeled RBC, as de-
scribed in Materials and Methods . After 10 min, >50% of
theAGE-RSA was concentrated in the liver, whereas the liver
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uptake of nonmodified 1251-RSA was consistently <10% of
theAGE-RSA values (Fig. 1A) . Tissue accumulation ofAGE-
RSA was not affected by the prior injection of 100-fold excess
nonlabeled RSA (5 mg, not shown) . In contrast, pre-treatment
of rats with excess nonlabeled AGE-RSA (5 mg) decreased
the accumulation ofAGE-RSA in the liver by ti45% after
10-, 20-, and 60-min intervals (Fig . 1 B) . The uptake ofAGE-
RSA remained uniformly low in all other major organs, with
or without the nonlabeled competitor. It was apparent that
the liver had a high specific capacity to accumulate AGE pro-
tein and therefore represented a potentially rich source for
the isolation of the AGE-binding proteins .
AGE-binding Assay .
￿
To facilitate the isolation oftheAGE-
binding proteins from liver, we developed a solid-phase assay
system involving the immobilization of detergent-solubilized
membrane proteins onto nitrocellulose and probing for ligand-
specific binding activity with 1251AGE-BSA as described in
Materials and Methods. Fig. 2A shows the effect of increasing
amounts of crude liver membrane proteins on AGE ligand
binding. Total AGE-BSA binding increases in proportion to
the amount of membrane proteins immobilized on the filters,
whereas nonspecific binding was negligible. The AGE-binding
kinetics of these membrane proteins after blotting onto
nitrocellulose is shown in Fig. 2B. When ti8 lAg of hepatic
membrane proteins immobilized onto NC filters were in-
cubated with increasing amounts of 1251-AGE-BSA, saturable
binding was observed with a B.. of 0.22 pmol/8 Ag of
protein (Fig. 2 C) . A dissociation constant (Ka of 4 x 10 -8
M) was revealed by Scatchard analysis of the binding data (31) .
The specificity of liver cell binding activity for AGE ad-
ducts on protein was determined in competition experiments
testing 1251-AGE-BSA against several different AGE protein
competitors, as well as against ligands known to bind to other
scavenger receptors (Fig. 2D) . The addition of 150-fold excess
AGE-RNAse or AGE-collagen I completely inhibited the
Figure 1.
￿
(A) In vivo tissue distribution of 1251-AGE.
RSA . 50 Wg of either 12 51-AGE-RSA (filled and striped
ban) or 1251-native RSA (shaded ban) were administered
intravenously to normal rats. At 10 min, the animals were
killed, and the organs and tissues were removed and
counted for radioactivity. Whole organ counts were cor-
rected forblood-associated counts as described in Materials
and Methods. (B) Specific competition of 1251-AGE-RSA
uptake in rat liver, spleen, lung, and kidney. Immediately
before receiving radiolabeled ligand, rats wereinjectedwith
excess nonlabeledAGE-RSA (5 mg, ix.). At the indicated
time intervals, incorporated radioactivity was determined
in blood and tissues, and compared according to a TBIR
formula as described in the text . (Closed and striped ban)
1251-AGE-RSA (50 t~g) alone; (Open ban) 1251-AGE-RSA
(50 )sg) in the presence ofexcess nonlabeled AGE-RSA .
Data are expressed as mean ± SEM ofthree independent
measurements performed in five animals per group .
Proteins in Rat LiverFigure 2 .
￿
AGE-binding activity assay. (A) Relationship of liver mem-
brane protein concentration to AGE-ligand binding . Aliquots (1-50 lAg)
of a detergent-solubilized liver membrane protein preparation were im-
mobilized on nitrocellulose filters, incubated with blocking buffer, and
then probed forAGE protein binding activity with 1251-AGE-BSA in the
presence or absence of excess nonlabeled AGE-BSA . After washing, the
blots were counted for 1251 . (Closed circles) 1251-AGE-BSA alone (total
binding) ; (open circles) 1251-AGE-BSA plus 100-fold excess nonlabeled AGE-
BSA (nonspecificbinding) . Data points represent duplicate blots. (B) Satura-
bility of 1251-AGE-BSA binding. A fixed amount ofsolubilized liver mem-
brane proteins (8 ug) was immobilized on duplicate nitrocellulose filters
which were probed with increasing concentrations of 125 1AGE-BSA
(10-100 nM, s.a. 1.5 x 105 cpm/ng) in the presence (nonspecific) or ab-
sence (totalbinding) of200-fold excess nonlabeledAGE-BSA . After washing,
the nitrocellulose filters were counted for retained 1251 . Specific binding
was determined by subtracting nonspecific binding from total binding.
(C Scatchard analysis ofspecificbinding data (B = pmol/8 Wgmembrane
protein, F = AM) . (D) Effects of differently modified protein ligands on
1251-AGE-BSA binding. Filter blots of solubilized liver membranes pre-
pared as above were probed with 1251-AGE-BSA (50 nM) alone, or in the
presence of 150-fold excess ofvarious nonlabeled competitors : AGE-BSA,
AGE-RNAse, AGE-collagen I, FFI-BSA, formaldehyde-treated albumin
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binding of radio-labeled AGE-BSA to crude hepatic mem-
brane protein extracts immobilized on NC filters . In con-
trast FFI-BSA, formaldehyde-treated BSA, glucosamide-BSA
(a chemically linked glucose-BSA compound) or acetyl-LDL
did not compete against the binding of labeled AGE-BSA .
Using similar detergent-solubilized membrane preparations
from heart, kidney, brain, or lung obtained by identical proce-
dures as described for liver, 1251-AGE-BSAspecific binding
activity was examined by the same solid-phase AGE-binding
assay. Liver membrane proteins exhibited the highest bind-
ing activityamong all tissues examined, consistent with our
in vivo observations (data not shown) .
Purification ofRat Liver AGE-binding Proteins.
￿
Using the
solid-phaseAGE binding assay as a means ofmonitoringAGE-
binding activity column fractions, we pursued the isolation
ofAGE-binding protein(s) by the procedure outlined in Table
1 and described in detail in Materials and Methods. In brief,
rat liver membrane proteins were solubilized in Triton X-114 .
After detergent phase-separation, the D phase was subjected
to chromatography on PEI-cellulose, DEAF-cellulose, BSA-
Sepharose, and finally, AGE-BSASepharose . After elution from
theAGE-BSA Sepharose column, the fractions were assessed
for AGE-binding activity by the solid-phase AGE binding
method (Fig. 3) . Analytical SDS-PAGE electrophoresis ofthe
active fractions obtained from theAGE-BSAcolumn revealed
the presence of two main protein bands with approximate
molecular masses of 60 kD (p60) and 90 kD (p90) (Fig. 3,
inset) . To separate larger amounts ofthese AGE-binding pro-
teins, AGE-BSA column eluate fractions were subjected to
preparative PAGE and the individual proteins were separately
electro-eluted from respective gel slices.
Gel-purified p60 and p90 were blotted onto Immobilon
membranes and NH2-terminal sequences were obtained at
The Rockefeller University sequencing facility . Table 2 records
the NH2-terminal sequence obtained from each of these pro-
teins. Comparison ofthese sequences with the translated Gen-
bank database did not reveal significant similarity to other
known proteins .
Ligand blotting ofp60 and p90 proteins immobilized on
nitrocellulose, using 1251-AGE-BSA as probe, revealed that
only the60-kD proteinbound this ligand (not shown). After
blotting on nitrocellulose, the 90-kD protein did not bind
1251-AGE-BSA, although p90 did bind to the AGE-BSA
Sepharose matrix and was not retained on the BSASepharose
column .
When crude rat liver membrane proteins (D phase) were
separated by SDS-PAGE under nonreducing conditions, trans-
ferred to NC filters, and probed for ligand binding with 1251-
AGE-BSA, a single majorAGE-BSA binding band at an ap-
proximate molecular mass of 60 kD was revealed (Fig. 4 A,
lane 1) . The binding of this protein to AGE-BSA was in-
hibited partially in the presence of a 25-fold excess (lane 2)
and completely by a 150-fold excess of nonradioactive AGE-
BSA (lane3) . No other prominent bands were observed under
(f-alb), glucosamide BSA, acetyl-LDL (act-LDL) . Data are expressed as
the amount of 1251AGE-BSA (cpm x 10- 3) retained on duplicate blots .Table 1.
￿
Purification of Rat Liver AGE-binding proteins
Figure 3.
￿
Purification of rat liver AGE-binding proteins. Detergent-
solubilizedmembrane proteins werefractionatedby successive PEI-cellulose,
DEAE-cellulose, and BSA-Sepharose 4B column chromatography, as de-
scribed in Materials and Methods. The flow-through from the BSA-
Sepharose column was then applied to an AGE-BSASepharose 4B column.
This column waswashed andbound proteins were elutedby the addition
ofhigh salt buffer. Each fraction was concentrated and analyzed for AGE-
binding activity using the binding assay described in Fig. 2 . (Open circles)
Total binding activity; (closed circles) nonspecific activity. (Inset)SDS-PAGE
analysis of fraction no . 8 (mercaptoethanol reduced), and stained with
Coomassie blue .
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Rat liver membrane proteins were procured and prepared as described. Specific binding ofAGE-BSA was determined by the solid phase binding assay .
`Binding activity could not be determined due to the presence of SDS .
these conditions . It thus appears likely that nitrocellulose im-
mobilization may inactivate the binding properties of p90,
or that p90 is a p60-associated protein that lacks independent
AGE-binding activity.
Immuno-characterization of AGE-binding Proteins .
￿
Purified
p60 and p90 proteins were injected into chickens in order
to obtain specific polyclonal antibodies . Preparation of avian
IgG specific for each ofthe proteins were isolated either from
egg yolk or serum as described in Materials and Methods .
The specificity ofeach ofthe antibodies was verified by Western
blot analysis, using the same crude liver membrane protein
extract analyzed above by ligand blotting (Fig . 4 B) . The an-
tibody to the p60 AGE-binding protein recognized a major
protein band at -60 kD (lane 2), while the pre-immuneIgG
did not (lane 1) . Similarly, the antibody to p90 recognized
a single protein band at -90 kD (lane 4), whereas the pre-
immune antibodies did not (lane 3) .
The antibodies to p60 and p90 were used to screen for the
expression of these proteins on the surface of rat pen'pheral
blood monocytes and peritoneal macrophages . FACS~ anal-
yses, which demonstrated the presence of each protein on
the surface of both cell types, are shown in Fig . 5 . Fig . 5,
A and B, illustrate flow cytometric detection of p60 and p90
on the surface of rat monocytes . Fig . 5 also shows that the
binding of either anti-p60 or anti-p90 to the monocyte cell
Table 2 .
￿
NHZ-terminal Amino Acid Sequence Analysis of
AGE-binding Proteins from Rat Liver
Size
￿
Sequence
60 kD :
￿
XGPRTLVLLDNLNVRDTHXLFF
90 kD :
￿
XEVKLPDMVSLXD
X indicates unidentified residues .
Purification
Step
Total
Protein
1251-AGE-BSA
Total
binding
Specific activity
Purification
factor Recovery
mg Ag 1~g1mg
Liver membrane 6,800 455.5 0.067 1 100
D-phase 830 207.5 0.256 3.7 45
PEI 175 262.2 1.498 22 58
DEAE 82 153.5 7.490 109 34
AGE-affinity 0.560 92.4 165 2463 20
Preparative PAGE" 0.180 -surface was not affected by a 20-fold excess of the heterolo-
gously directed antibody (C and D, respectively) . Distinct
binding ofanti-p60 and anti-p90 antibodies was also observed
when the rat peritoneal resident macrophages were analyzed
by flow cytometry (Fig. 5, E and F, respectively) . A small
subgroup of highly fluorescent cells of an unspecified nature
with a nonspecific FITC staining pattern was also noted, using
antibody as well as isotypic controls .
To confirm that p60 and p90 were both AGE-binding pro-
teins expressed independently on rat peritoneal resident mac-
rophages, 1251-AGE-BSA binding inhibition experiments
were carried out using each antibody separately (undiluted :
10 Ag/ml) as well as in combination (Fig. 6A) . In the pres-
ence of increasing concentrations of anti-p60 antibody,
significant AGE-BSA binding inhibition was observed (up
to 80% at a final concentration of 10 Fcg/ml) . Similarly 1251-
AGE-BSA binding was inhibited up to 60% by the anti-p90
antibody, while the combination of both antibodies at a di-
lution of 1:10 provided 84% inhibition . When radiolabeled
FFI-BSA (made from the chemically synthesized model AGE
compound, FFI) (13) was used as the ligand, anti-p60 as well
as anti-p90 mediated a concentration-dependent inhibition
of FFI-modified BSA binding (Fig. 6 B) . Moreover, and as
found with AGE-BSA, a combination of anti-p60 and anti-
p90 antibodies exerted greater inhibition compared to either
anti-p60 alone or anti-p90 alone. No inhibitory effect was
noted when isotypic control antibodies were used, even at
the maximal concentration, in conjunction with either
modified BSA ligand (data not shown) .
Discussion
In the present communication, we describe the isolation of
two novel rat livermembrane proteins, designated p60 and p90
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Figure 4 .
￿
(A) Ligand blot analysis of rat liver membrane
proteins. Aliquots (15,ug each)ofdetergent-solubilized mem-
brane proteins were subjected to electrophoresis through
8-16% acrylamide gradient gel under nomeducing conditions
and electro-transferred onto nitrocellulose filters. Using 12s1-
AGE-BSA (50 nM, 8.0 x 105 cpm/ng) as probe, specific
binding was determined in the presence of 0-, 25-, or 150-
fold excess nonlabeled AGE-BSA using autoradiographic de-
tection. Migration of molecular mass standards is shown at
left. (B) Aliquots of solubilized membrane proteins (mercap-
toethanol reduced), were subjected to electropboresis through
an 8-16% gradient gel and electro-transferred onto nitrocel-
lulose filters. After washing and blocking with excess BSA,
the blots were probed with purified IgG fractions of either
anti-p60 or anti-p90 chicken antisera or the corresponding
preimmune sera, and then exposed to goat anti-chicken anti-
body conjugated to alkaline phosphatase and reacted for
phosphatase-dependent color development. Lane 1, preimmune
IgG ; lane 2, anti-p60 IgG ; lane 3, preimmune IgG, lane 4,
anti-p90 IgG. Results are representativeof three independent
experiments.
by their migration inSDS-PAGE, which specifically bind to
protein ligands modified by AGES . NH2-terminal sequence
analysis indicates that these proteins bear no significant ho-
mology to each other nor to any previously sequenced pro-
teins currently available in the Genbank database. Both p60
and p90 are present on rat monocytes and macrophages and
are immunoreactively and functionally distinct . Of impor-
tance is the fact that these binding proteins have been distin-
guished from both the recently reported macrophage scav-
enger receptor for acetyl-LDL, a functional trimer composed
of three 77-kD glycoprotein subunits (32), and from the
binding proteins for formaldehyde-treated albumin withMr s
of 30 and 52 kD (33) .
The p60 and p9O AGE-binding proteins were isolated from
rat liver, once we had determined that this organ acts as a
major filter for the in vivo clearance of AGE-modified mac-
romolecules ; liver presents the highest capacity to specifically
sequester AGE proteins administered intravenously (Fig . 1) .
An isolation procedure, including elution of detergent-
solubilized membrane proteins from an AGE-protein affinity
matrix, was devised, and the p60 and p90 AGE-binding pro-
teins were found to copurify . When immobilized on nitrocel-
lulose, however, only p60 retained binding activity for AGE-
modified ligands. Just as they copurified over anion exchange
and ligand affinity columns, p60 and p90 were also observed
to co-purify in hydroxylapatite chromatography (data not
shown) . Further experimentation is required to determine
whether this copurification is fortuitous, or due to molec-
ular interaction between the 60- and 90-kD proteins.
The liver is a complex organ containing several cell types,
including macrophages and endothelial cells, both of which
have been shown to bear AGE-receptors (3-6, 10, 30) . It is
alternatively possible that the distinct AGE-binding proteins
we isolated from whole liver originated from different popu-
lations ofcells, or that each protein was expressed with different200
200
Log fluorescence intensity
Figure 5 .
￿
Demonstration by flow cytometry of expression ofp60 and
p90 AGE-binding proteins on rat monocytes and macrophages . Peripheral
blood monocytes (A-D) and peritoneal resident macrophages (E and F)
were treated with biotinylated anti-p60 alone (A andE), biotinylated anti-
p90 alone (B andF), biotinylated anti-p60 + 20-fold excess unconjugated
anti-p90 (C), biotinylated anti-p90 + 20-fold excess unconjugated anti-p60
(D), followed by FITC-avidin and analyzed by FACSCAN® . (Arrow 1)
Fluorescence of cells treated with FITC-avidin in the absence of either
anti-p60 or anti-p90 (dotted line) . (Arrow 2) Fluorescence of cells treated
with FITC-avidin subsequent to treatment withbiotinylated chicken IgG
(isotypic control) . (Arrow 3) Fluorescence of cells treatedwithFITC-avidin
subsequent to treatment of cells with biotinylated anti-p60 (A, C, and
E) and anti-p90 (B, D, and F) . Note the lack of competition between
a 20-fold excess of unconjugated anti-p90 for the binding of anti-p60 to
the monocytes (panelA vs . C), and the lack of competition between a
20-fold excess of unconjugated anti-p60 for the binding of anti-p90 to
the monocyte cell surface (panelB vs . D) . All antibodies were used at a
final concentrations of 5 jug/ml, unless otherwise indicated .
affinity and/or at a different density in a cell-specific manner.
A 90-kD protein that binds to AGE-BSA, as well as to the
chemically synthesized AGE model compound, FFI, has been
previously described on murine macrophages (4, 8, 9, 13) .
To determine whether macrophages also expressed a 60-kD
AGE-binding protein, and whether there was any relation-
ship between the macrophage 90-kD and the liver p90 AGE-
binding proteins, specific polyclonal antibodies to liver p60
and p90 were developed .
The specificity of these antibodies was demonstrated by
Western analysis of crude livermembrane extracts, revealing
that each antiserum identified a single protein band of the
appropriate molecular weight . Flow cytometric analysis of
rat peripheral monocytes and peritoneal resident macrophages
revealed that each antisera bound to the surface of both of
these cell types. Crosscompetition studies performed onmono-
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cytes revealed no crossreactivity between thetwo antibodies.
These data indicate that the p60 and p90 AGE-binding mol-
ecules originally isolated from whole liver preparations are
each present on monocytes as well as macrophages (Fig. 5) .
Flow cytometric binding inhibition experiments clearly
demonstrated that p60 and p90, expressed on the surface of
monocytes/macrophages, independently bound AGE-modified
ligands. Interestingly, a combination of antibodies specific
for p60 and p90 mediated greater inhibition of AGE-protein
binding than did either antibody alone.
Either antiserum, used independently or in combination,
prevented >90% of binding of FFI-BSA to rat macrophages .
In the case of p60, this finding is surprising given that this
binding protein does not bind FFI-BSA in a solid-phase ligand
blotting assay. Possibly, the binding affinity of this receptor
protein for the FFI moiety is lower than that for other AGE
structures contained in the heterogeneous AGE-modified pro-
tein preparations . With regard to liver p90, the flow cytom-
etry and FFI-binding inhibitory data indicate that this mole-
culemay be closely related to the 90-kD protein isolated from
murineRAW 264.7 cells (9) . In fact, preliminary experiments
using antibodies raised against rat liver p60 and p90 proteins
to stain mouse RAW cells provided flow cytometric and
binding inhibition results similar to those obtained with rat
monocytes and macrophages, strongly supporting a struc-
tural similarity between the AGE-binding proteins of these
two rodent species.
There are several ways that these binding results, taken in
sum, might be interpreted : it is possible that the p60 and
p90 proteins represent structurally distinct subunits ofa single
receptor complex, each of which binds AGE moieties with
differential affinity. Alternatively, both proteins may be present
in equimolar concentration on the cell surface, but only p60
binds AGES, while p90, although necessary to stabilizeAGE
binding, is itself incapable of independently immobilizing
AGE ligands . The ability of the anti-90 antiserum to block
AGE-binding according to this second interpretation would
reflect a perturbation of p60-mediated AGE protein binding
activity via the interaction of antibody with p90, suggesting
that p60 and p90 exist in close association .
The AGE-specific receptor system now includes a variety
oftissues and cell types in addition to monocyte/macrophages
for which receptor-mediated AGE-protein internalization and
digestion was first described (3, 4, 30) . Endothelial cells (10),
mesangial cells (11), and fibroblasts (12) have since been shown
to specifically bind AGE-modified proteins (8) . In macro-
phages, AGE protein uptake is accompanied by the release
of a variety of potent cytokines and growth factors (5-7),
whichmay coordinate processes of normal tissue remodeling .
The other cell types do not bind the model compound AGE,
FFI, nor are they known to release cytokines and growth
factors in response to AGE-ligand binding, but each cell type
does display distinct functional responses. For example, en-
dothelial cells exhibit enhanced surface procoagulant activity
and permeability (10), mesangial cells display enhanced ma-
trix protein synthesis (11), while human fibroblasts exhibit
increased proliferation upon exposure to AGEs (12) . Although
Advanced Glycosylation Endproduct-binding Proteins in Rat Liverour understanding of the receptor-mediated effects ofAGES
is at an early stage, it is possible that there maybe a family
of AGE-binding proteins, distributed among different tissues,
with distinct spectra ofligand specificities and induciblefunc-
tions. In addition, giventhebroadheterogeneityofAGE moi-
eties, onemight anticipate the cooperation of more than one
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